SOX5 and rheumatoid arthritis: Importantly, our data indicated that SOX5 only showed weak binding activity with RANKL in unstimulated SF; however, this binding activity was markedly enhanced after IL-6 treatment in the RA synovium derived cell line, MH7A in our ChIP assay.